This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A third look: Discussing the phase I data on ViiV Healthcare's long-acting cabotegravir (CAB-ULA) for HIV
Ticker(s): VIIV HEALTHCAREWho's the expert?
Instituition: University of Maryland
- Associate Professor of Medicine at the University of Maryland School of Medicine and Institute of Human Virology (IHV).
- Medical Director for the IHV's Center for International Health, Education, and Biosecurity (Ciheb).
- worked extensively in Rwanda since 2008 but has also served in other countries including Kenya, Malawi, and Zambia. His research in the US focuses on HIV-related cancers, and he runs the Infectious Diseases fellowship training program at the University of Maryland.
Interview GoalThis interview will focus on discussing the standard of care and the recent phase I clinical trial results of a new cabotegravir long-acting injectable formulation by ViiV Healthcare, which offers extended dosing intervals.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
